BIOA vs CLDX: fair value comparison
BioAge Labs, Inc. and Celldex Therapeutics, Inc. · Updated 2026-10-19
BIOA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. CLDX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, BIOA currently ranks higher by quality score.
| BIOA | CLDX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $4.84 | $27.53 |
| 12-month range | $4.84–$25.10 | $22.58–$44.87 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #180 of 301 Healthcare | #182 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: BIOA fair value analysis · CLDX fair value analysis